adverse event reporting - July, p. 200; Nov., p. 331

AIDS activists - Nov., p. 326

AIDSDRUGS database - Apr., p. 105

AIDSLINE database - Apr., p. 105

AIDSPAT, Internet news group - Dec., p. 363

AIDSTRIALS database - Apr., p. 105

animal therapeutics approvals - Oct., p. 297

approval, U.K. - Feb., p. 40

approvals - Mar., p. 74

approvals, accelerated - June, p. 161; Aug., p. 225; Sep., p. 259, 261, 262

AZT sales - Apr., p. 103

baboons, HIV models - Nov., p. 330

bankruptcy - July, p. 202

Canada - June, p. 170

clinical trial regulations - Nov., p. 331

clinical trials halted - Feb., p. 33; Aug., p. 230; Nov., p. 326

clinical trials - Feb., p. 34, 37, 38, 40; Mar., p. 65, 67, 68, 69, 71, 72, 73, 74, 75; Apr., p. 97, 99, 101, 102, 103; May, p. 129, 130, 131, 133, 134, 135, 137, 138; June, p. 165, 166, 168, 171; July, p. 200, 201; Aug., p. 225, 226, 227, 229, 230, 231, 232, 233; Sep., p. 261, 262, 268; Oct., p. 289, 290, 291, 293, 295, 296, 297; Nov., p. 321, 323, 324, 325, 327, 328, 329, 330; Dec., p. 353, 356, 357, 358, 359, 360, 361, 362, 363

clinical trials, large-scale HIV - June, p. 164; July, p. 194; Nov., p. 324

co-promotion agreements - July, p. 199

Collaborative Research and Development Agreements (CRADAs) - Mar., p. 75; Oct., p. 301

community-based trials - Sep., p. 269

Concorde Study - April, p. 99

contract awards - Feb., p. 43; Mar., p. 75; June, p. 170

corporate disputes - Mar., p. 72; June, p. 171

corporate linkages - Feb., p. 33, 36, 41; Mar., p. 70, 73; Apr., p. 101, 102, 103; May, p. 131, 138, 139; June, p. 172; July, p. 199; Aug., p. 232; Sep., p. 267; Oct., p. 296; Nov., p. 325, 330; Dec., p. 359, 362, 363

corporate restructuring - May, p. 138; Aug., p. 230, 233; Sep., p. 267; Oct., p. 296; Nov., p. 326, 331; Dec., p. 360

criminal charges - Feb., p. 42

crystal structures - Mar., p. 70

cytokine validation - Nov., p. 331

cytotoxic T-cell immunity - Feb., p. 36

databases - Apr., p. 105; Nov., p. 332; Dec., p. 363

Directory of Biotechnology Information Resources - Apr., p. 105

drug approvals - July, p. 202

epidemiology - Apr., p. 102; July, p. 197; Aug., p. 227; Sep., p. 257; Dec., p. 355, 360

establishment license revoked - Feb., p. 42

ethnobotany - Dec., p. 360

European Community - June, p. 172

expanded access - Nov., p. 326

extortion - June, p. 171

FDA approvals - Feb., p. 35; July, p. 193; Aug., p. 225, 226, 227; Nov., p. 323; Dec., p. 363

Federal Bio-Technology Transfer Directory - Mar., p. 75

Finland - Dec., p. 362

food additives, antiviral - Feb., p. 44

France, approvals - Feb., p. 41

gene amplification - Apr., p. 102

grant awards - Apr., p. 104; May, p. 139; June, p. 170; July, p. 204; Sep., p. 268, 269; Nov., p. 332

heat sensitivity, HIV - Dec., p. 362

HIV radiodiagnostic imaging - Nov., p. 332

HIV research grants, minorities - June, p. 172

HIV reservoirs - Aug., p. 228

HIV viral burden - Aug., p. 228

HIV-infection co-factors - Apr., p. 100

HIV-infection from vaccines - June, p. 164

HuMab-Mouse system - July, p. 204

Human Immunodeficiency Virus (HIV) Research Program - Feb., p. 42

injunctions granted - Dec., p. 364, 366

insider trading - July, p. 200; Dec., p. 359, 362

Israeli markets - Feb., p. 41

Japan - Aug., p. 230

Journal of Chronic Fatigue Syndrome - Oct., p. 299

Journal of Pharmaceutical Care in HIV/AIDS Treatment - May, p. 139

lab safety, HIV - June, p. 173

licensing - Feb., p. 36, 39, 41, 44; Mar., p. 74, 76; Apr., p. 98, 102, 104, 106; May, p. 131, 171; June, p. 174; July, p. 205; Aug., p. 230, 232, 235; Sep., p. 264, 270; Oct., p. 293, 296, 297, 300, 301; Nov., p. 328, 330; Dec., p. 358, 359, 362, 363

licensing, federal government - Mar., p. 75

ligase chain reaction - Apr., p. 102

long-term survivors, HIV - Aug., p. 228

manufacturing facilities - Aug., p. 233

mice testing - Mar., p. 72

mucosal immunity - July, p. 204

mucosal vaccines - Mar., p. 77

NDA filings - Feb., p. 34; June, p. 171; Aug., p. 227

new companies - July, p. 201; Oct., p. 297

NIH budget - Mar., p. 75

oligonucleotide synthesis - Nov., p. 325

Orphan Drug Act - Apr., p. 103

patent disputes - May, p. 140; June, p. 169; July, p. 204; Aug., p. 236; Sep., p. 270; Oct., p. 300; Nov., p. 333; Dec., p. 362, 364, 366

patent disputes, HIV - July, p. 202

patent infringement - Feb., p. 41; Apr., p. 103

patent licensing (use licensing)

patents, AIDS-related full text - Dec., p. 363

pediatric trials - Oct., p. 296

Peoples Republic of China - Dec., p. 362

polymerase chain reaction (PCR) - Apr., p. 102

price controls - Mar., p. 73

pricing, federal inventions - Dec., p. 364

primate studies - July, p. 194; Oct., p. 292

public education - July, p. 197

quality of life - Mar., p. 67

R&D halted - Oct., p. 296; Dec., p. 359

recruiting, HIV vaccine trials - Feb., p. 40

research integrity - Feb., p. 42

Samoa - Aug., p. 235

SCID-hu mouse studies - Nov., p. 325

screening - Mar., p. 74; Apr., p. 101, 103; July, p. 206; Sep., p. 269; Dec., p. 364

surrogate markers - Sep., p. 259

TH1 to TH2 switch - Feb., p. 36

Thailand - Feb., p. 35; June, p. 171; Nov., p. 324

transgenic mice - July, p. 204

treatment costs, HIV-infection - July, p. 202

U.K. approvals - July, p. 202

unapproved treatments - Feb., p. 44

universal vaccinations - Dec., p. 362

vaccine heat stability - Apr., p. 102

viral load, HIV - Oct., p. 297

viral resistance, hepatitis C - Aug., p. 232

viral resistance, HIV - Mar., p. 69

viral shedding, HSV - Oct., p. 290

Virology on CD-ROM - Oct., p. 299

virus names - Aug., p. 233

warning letters, FDA - June, p. 165

warning letters, Japan - June, p. 169